(CercleFinance.com) – Guerbet loses nearly 8% in Paris, penalized by an analysis by Oddo which confirms its ‘neutral’ opinion on the share while lowering its target price from 35.3 to 32.5 euros, with the update of its risk parameters (WACC at 8% against 7.7% previously), after the publication of annual results deemed ‘satisfactory’.
The design office recognizes that the 2021 figures for the medical imaging group have been shown to be in line, with in particular a 2021 EBITDA margin in line with the guidance, and considers that the CSR achievements and objectives are ‘encouraging’.
“The short-term perspective gives the impression of a year 2022 characterized by many parameters of uncertainty, as well as investments preparing the period 2023-2025 and implicitly, a year 2022 of transition”, estimates the analyst however.
Copyright © 2022 CercleFinance.com. All rights reserved.
Did you like this article ? Share it with your friends with the buttons below.
